Safety and efficacy of endoscopic treatment with mucosal resection, radiofrequency ablation, and cryotherapy in the curative treatment of early esophageal squamous cell cancer and dysplasia.

4055 Background: Endoscopic esophageal treatment (EET), by radiofrequency ablation (RFA), cryoablation (Cryo), and endoscopic mucosal resection (EMR) has not been extensively studied in early esophageal squamous cell carcinoma (SCC). Aim: To assess the safety and success of EET in curative treatment of early esophageal SCC: (T1a, T1b, T2) and squamous cell dysplasia (SCD). Methods: We retrospectively reviewed records of patients with SCC (T1a, T1b, T2) and SCD treated with EET from January 2010 to August 2024. All patients had at least one follow-up endoscopic biopsy after treatment. Results: 62 patients met the eligibility criteria. Table. 46 patients (74%) had T1a (n=36.5%) or T1b (n=10.1%) SCC. T2 patients (21%) received ETT for local recurrence after chemoradiation. The most frequent ETT was EMR + RFA, n= 26 (41.9%) and RFA, n=20 (32%). In the first biopsy after treatment, 46 of the 62 patients (74.1%) had no residual cancer. This number increased after further ETT. 2 years after treatment only 4 patients had persistent cancer. BMI is significantly associated with survival status. No patient had disease progression that required surgery. Strictures formed in 15 patients (24%) post- ETT. Conclusions: ETT provides curative treatment of early SSC in up to 94% of patients. Association between cancer persistence at first post-biopsy with various demographic and clinical variables. Patient Characteristics Total N=62 P-value Sex (%) Male 28 (45.16%) 0.49 Female 34 (54.84%) Race (%) White / Caucasian 52 (83.87%) 0.716 Hispanic 2 (3.23%) Black 2 (3.23%) Asian 4 (6.45%) BMI, median (range) N = 62 24.02 (15, 44.5) 0.045 Smoking Status (%) No 25 (40.32%) 0.182 Yes 37 (59.68%) Alcohol Drinking (%) No 22 (35.48%) &gt;0.99 Yes 40 (64.52%) Squamous Dysplasia (%) none 59 (95.16%) &gt;0.99 Low 1 (1.61%) High 2 (3.23%) Squamous tumor staging (%) none 3 (4.84%) 0.174 T1a 36 (58.06%) <jats:td colspan

Authors

Institutions

Publication Details

Journal
Journal of Clinical Oncology
Published
2025-05-28
DOI
https://doi.org/10.1200/jco.2025.43.16_suppl.4055
Primary Topic
Esophageal Cancer Research and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Safety and efficacy of endoscopic treatment with mucosal resection, radiofrequency ablation, and cryotherapy in the curative treatment of early esophageal squamous cell cancer and dysplasia.

Mehnaz A. Shafi, Sidra Naz, Ahmed Elhariri, Matthew Manuel et al.
1 links
Journal of Clinical Oncology
Esophageal Cancer Research and Treatment
article

Safety and efficacy of endoscopic treatment with mucosal resection, radiofrequency ablation, and cryotherapy in the curative treatment of early esophageal squamous cell cancer and dysplasia.

Mehnaz A. Shafi, Sidra Naz, Ahmed Elhariri, Matthew Manuel, Wei Qiao, Marta Davila
article en

Abstract

4055 Background: Endoscopic esophageal treatment (EET), by radiofrequency ablation (RFA), cryoablation (Cryo), and endoscopic mucosal resection (EMR) has not been extensively studied in early esophageal squamous cell carcinoma (SCC). Aim: To assess the safety and success of EET in curative treatment of early esophageal SCC: (T1a, T1b, T2) and squamous cell dysplasia (SCD). Methods: We retrospectively reviewed records of patients with SCC (T1a, T1b, T2) and SCD treated with EET from January 2010 to August 2024. All patients had at least one follow-up endoscopic biopsy after treatment. Results: 62 patients met the eligibility criteria. Table. 46 patients (74%) had T1a (n=36.5%) or T1b (n=10.1%) SCC. T2 patients (21%) received ETT for local recurrence after chemoradiation. The most frequent ETT was EMR + RFA, n= 26 (41.9%) and RFA, n=20 (32%). In the first biopsy after treatment, 46 of the 62 patients (74.1%) had no residual cancer. This number increased after further ETT. 2 years after treatment only 4 patients had persistent cancer. BMI is significantly associated with survival status. No patient had disease progression that required surgery. Strictures formed in 15 patients (24%) post- ETT. Conclusions: ETT provides curative treatment of early SSC in up to 94% of patients. Association between cancer persistence at first post-biopsy with various demographic and clinical variables. Patient Characteristics Total N=62 P-value Sex (%) Male 28 (45.16%) 0.49 Female 34 (54.84%) Race (%) White / Caucasian 52 (83.87%) 0.716 Hispanic 2 (3.23%) Black 2 (3.23%) Asian 4 (6.45%) BMI, median (range) N = 62 24.02 (15, 44.5) 0.045 Smoking Status (%) No 25 (40.32%) 0.182 Yes 37 (59.68%) Alcohol Drinking (%) No 22 (35.48%) &gt;0.99 Yes 40 (64.52%) Squamous Dysplasia (%) none 59 (95.16%) &gt;0.99 Low 1 (1.61%) High 2 (3.23%) Squamous tumor staging (%) none 3 (4.84%) 0.174 T1a 36 (58.06%) <jats:td colspan

Journal of Clinical OncologyVol. 43(16_suppl)
The University of Texas MD Anderson Cancer Center (US)
Openalex Percentile: Top 79%
Esophageal Cancer Research and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.